Related references
Note: Only part of the references are listed.Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis
W. Kruis et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
5-Aminosalicylates Prevent Relapse of Crohn's Disease After Surgically Induced Remission: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
Nicholas J. Talley et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
ONCE DAILY ASACOL® IN MAINTENANCE THERAPY FOR ULCERATIVE COLITIS: A ONE-YEAR SINGE-BLIND RANDOMISED TRIAL
A. B. Hawthorne et al.
GUT (2011)
Review article: understanding adherence to medication in ulcerative colitis - innovative thinking and evolving concepts
S. V. Kane et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial
G. R. Lichtenstein et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Once-Daily Dosing of Delayed-Release Oral Mesalamine (400-mg Tablet) Is as Effective as Twice-Daily Dosing for Maintenance of Remission of Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2010)
Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial
Sunanda Kane
Patient Preference and Adherence (2010)
Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX® with Asacol®
C. Prantera et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares
P. D. R. Higgins et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis
Axel U. Dignass et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
M. A. Kamm et al.
GUT (2008)
The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States
Michael D. Kappelman et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted county, Minnesota, 1940-2000
Conor G. Loftus et al.
INFLAMMATORY BOWEL DISEASES (2007)
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis
Gary R. Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis
Michael A. Kamm et al.
GASTROENTEROLOGY (2007)
Systematic review: adherence issues in the treatment of ulcerative colitis
SV Kane
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Measuring therapy adherence in Parkinson's disease: a comparison of methods
KA Grosset et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2006)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease
MJ Shale et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Medication Nonadherence and the outcomes of patients with quiescent ulcerative colitis
S Kane et al.
AMERICAN JOURNAL OF MEDICINE (2003)
Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters
FN Hussain et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival
EV Loftus et al.
GUT (2000)